Lab
Total Lab Solutions LLC
Total Lab Solutions LLC was paid $768K by Medicaid between Mar 2023 and Dec 2024, across 81 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 31% of everything it billed.
33Billing provider infoTOTAL LAB SOLUTIONS LLC
TROY, MI 48083
TROY, MI 48083
33aNPI1750018370assigned 08/03/2022
33bProvider typeClinical Medical Laboratory
28Total paid$768K
24GClaims30,743
24DCodes billed81
24AFirst – last monthMar 2023 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#49 of 108
Median peer was paid$588K
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 9,223 | $157K | |
| 2024incomplete | 21,520 | $612K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 31% | 2,156 | 1,828 | $236K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 10% | 2,154 | 2,011 | $80K |
| 87481 | 9.7% | 1,581 | 1,378 | $74K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.5% | 1,052 | 968 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.0% | 1,724 | 1,675 | $39K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 4.8% | 660 | 620 | $37K |
| 87590 | 3.5% | 1,533 | 1,486 | $27K | |
| 87563 | 2.7% | 920 | 895 | $20K | |
| 87653 | 2.3% | 923 | 808 | $18K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.2% | 334 | 330 | $17K |
| 87631 | 2.1% | 249 | 243 | $16K | |
| 87808 | 1.6% | 1,498 | 1,453 | $13K |
69 more codes
| 87625 | 1.5% | 619 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.0% | 427 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 962 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 1,375 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 531 | $7K |
| 87641 | <1% | 353 | $7K | |
| 87500 | <1% | 361 | $7K | |
| 87511 | <1% | 318 | $6K | |
| 80061 | Lipid panel | <1% | 941 | $6K |
| 86780 | <1% | 788 | $6K | |
| 86695 | <1% | 714 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,335 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 271 | $5K |
| 87640 | <1% | 302 | $5K | |
| 87529 | <1% | 146 | $4K | |
| 80074 | <1% | 141 | $4K | |
| 84439 | <1% | 829 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 185 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 161 | $3K |
| 82607 | <1% | 369 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 613 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 567 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 798 | $2K |
| 84481 | <1% | 239 | $2K | |
| 83735 | <1% | 372 | $1K | |
| 82728 | <1% | 177 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 92 | $776.15 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 23 | $738.63 |
| 80350 | <1% | 69 | $726.45 | |
| 80348 | <1% | 58 | $725.00 | |
| 80354 | <1% | 72 | $721.68 | |
| 83540 | <1% | 219 | $716.37 | |
| 83550 | <1% | 157 | $683.06 | |
| 80356 | <1% | 69 | $675.00 | |
| 80365 | <1% | 72 | $578.44 | |
| 84153 | <1% | 69 | $566.16 | |
| 80367 | <1% | 72 | $475.71 | |
| 80373 | <1% | 73 | $475.00 | |
| 80372 | <1% | 72 | $475.00 | |
| 80363 | <1% | 36 | $444.92 | |
| 83880 | <1% | 26 | $441.30 | |
| 83992 | <1% | 69 | $378.48 | |
| 80323 | <1% | 20 | $320.30 | |
| 84100 | <1% | 124 | $320.20 | |
| 80324 | <1% | 19 | $300.00 | |
| 80338 | <1% | 21 | $292.30 | |
| 80336 | <1% | 20 | $263.65 | |
| 80333 | <1% | 16 | $245.38 | |
| 86696 | <1% | 52 | $228.96 | |
| 80344 | <1% | 20 | $228.87 | |
| 80349 | <1% | 17 | $206.64 | |
| 87070 | <1% | 41 | $203.51 | |
| 80346 | <1% | 15 | $193.98 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $171.84 |
| 80355 | <1% | 21 | $167.58 | |
| 80360 | <1% | 20 | $137.76 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34 | $97.08 |
| 80366 | <1% | 20 | $91.84 | |
| 80368 | <1% | 20 | $91.10 | |
| 80361 | <1% | 17 | $91.08 | |
| 80370 | <1% | 20 | $86.34 | |
| 80364 | <1% | 12 | $76.72 | |
| 83090 | <1% | 12 | $54.92 | |
| 80358 | <1% | 13 | $50.00 | |
| 86140 | <1% | 13 | $30.03 | |
| 85652 | <1% | 14 | $20.16 | |
| 82565 | <1% | 16 | $19.20 | |
| 83789 | 0% | 145 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 62 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZACK, SCOTT (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Boulder GX | Spring, TX | $120K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.